cASE STUDY #3
Long term strategic HEOR partnership
To provide long-term strategic HEOR and market access support for a fully human monoclonal antibody in the treatment of a severe orphan disorder with Breakthrough status in the US and PRIME status in the EU. To ensure best quality advice through development of a collaborative partnership.
The initial step was to develop a prioritised and phased global (US + Europe) market access, pricing and reimbursement evidence generation plan for market access for the monoclonal antibody.
Vitaccess provided ongoing support in the execution of the evidence generation plan. Some projects were undertaken in-house. For those that were not, Vitaccess evaluated prospective vendors and undertook day-to-day management of the vendors during the studies. This included development of briefing packs and RFPs, prospective vendor selection, review and evaluation of proposals received and recommendation of preferred bidder, and management of vendors.
Vitaccess also provided ad hoc market access, pricing and reimbursement advice when required.
Despite an accelerated timeline for first commercial launch and plans to implement a patient access programme the client had limited internal resources available in the short-term, as well as a need to support corporate activity.
We undertook an approach which leveraged our existing experience to enable us to deliver results in 6-8 weeks from project initiation. The aggressive timelines were achieved by using a web-based survey approach, and comprehensive briefing materials. We required respondents to complete a preliminary e-learning module to ensure they understood the complexities of the disease and treatments, and to sequentially review materials as part of the web survey prior to eliciting formal feedback.